1 BTC
=
- USD
Biote Corp. Class A Common Stock
As of May 31, 2026 at 24:02 UTC
Chart
About Biote Corp. Class A Common Stock
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
Market Statistics
Trading Metrics
How to Buy BTMD
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy BTMD
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe article highlights four stocks - Steelcase, Carriage Services, biote, and Acme United - that have seen rising cash flows, making them good investment options. The article emphasizes the importance of analyzing a company's cash position and net cash flow as indicators of financial health and growth potential.
The article suggests that stocks with rising cash flows, such as Ardmore Shipping Corporation, TXO Partners, L.P., GeoPark Limited, and biote Corp., are worth buying as they have the flexibility to weather market uncertainties and support growth. The article emphasizes the importance of analyzing a company's cash-generating efficiency to assess its true financial health.
Haemonetics is benefiting from growth in its Plasma, Hospital, and Hemostasis Management segments, driven by new product launches and market share gains. The company's hospital portfolio is evolving, creating new growth opportunities. However, it faces challenges from inflationary pressures and supply chain disruptions.
